Gastroenterology - Digestive Immunology

Anti-endomysium IgA | Clinique Omicron Québec

Anti-endomysial IgA antibodies (AEM IgA) are autoantibodies directed against endomysium, a layer of connective tissue surrounding smooth muscle fibers. Their main antigenic target is tissue transglutaminase type 2 (TG2), an enzyme involved in the cross-linking of intestinal extracellular matrix proteins. These antibodies are one of the most specific serological markers of celiac disease, an autoimmune enteropathy triggered by gluten ingestion in genetically predisposed individuals. Their diagnostic specificity exceeds 97-99 % in most studies, making them a valuable tool when the results of other markers, notably IgA anti-transglutaminase, are ambiguous. Celiac disease affects around 1 % of the world's population, although a significant proportion of cases remain undiagnosed. The AEM IgA assay is part of a structured serological work-up, always performed in a patient maintaining a gluten-containing diet, to ensure the validity of the results.

Mechanism and antigenic target

The endomysium is largely composed of collagen and extracellular matrix proteins. Tissue transglutaminase 2 (TG2), identified as the primary autoantigen recognized by IgA EMA, is a ubiquitous enzyme that is particularly abundant in the small intestinal mucosa. In celiac individuals, TG2 deaminates glutamine residues of gliadin peptides, producing neoantigens that activate the adaptive immune response.

This activation generates the production of autoantibodies, including EMA IgA, and triggers chronic inflammation of the duodenal mucosa leading to the villous atrophy characteristic of untreated celiac disease. Normalization of EMA IgA under a strict gluten-free diet indicates therapeutic response and progressive restoration of the intestinal lining.

ℹ️ The dosage of IgA EMA should always be accompanied by a dosage of total IgA. An IgA deficiency (frequency of approximately 1 in 500), which is more common in celiac individuals than in the general population, can lead to a false negative. In case of a confirmed deficiency, the assessment should be supplemented with IgG-type antibodies (anti-TG2 IgG, anti-DGP IgG).

Dosage indications

EMA IgA testing is indicated in several clinical contexts, alone or in addition to anti-tissue transglutaminase IgA (anti-TG2 IgA), which represents the first-line test according to most current guidelines.

Clinical suspicion of celiac disease in the presence of persistent digestive symptoms: chronic diarrhea, bloating, abdominal pain, malabsorption
Suggestive extradigestive symptoms: refractory iron-deficiency anemia, early osteoporosis, unexplained infertility, chronic fatigue
Equivocal or weakly positive anti-TG2 IgA result requiring confirmation
Screening of first-degree relatives of a confirmed celiac patient
Autoimmune conditions associated with increased risk: type 1 diabetes, Hashimoto's thyroiditis, Down syndrome, Turner syndrome
Serological monitoring of a known celiac patient on a gluten-free diet, to assess adherence and therapeutic response

Results Interpretation

IgA AEM are most often reported qualitatively (positive or negative) by indirect immunofluorescence on monkey esophagus or human umbilical cord, or by quantitative ELISA method depending on the laboratory. Their interpretation must take into account the clinical context and the patient's IgA status.

Result	Probable interpretation	Action to take
Positive (normal IgA)	Strong suspicion of active celiac disease	Reference in gastroenterology for confirmatory duodenal biopsy
Negative (normal IgA)	Celiac disease unlikely if gluten diet is maintained	Consider other diagnoses; re-evaluate if symptoms persist
Negative (IgA deficiency)	Possible false negative; uninterpretable result	Complete with anti-TG2 IgG and anti-DGP IgG
Positive on a gluten-free diet	Probable food transgression or normalization delay	Membership review for the program; serological follow-up at 6 months
Gluten-free negative	Good response to the diet, serological normalization	Confirm the histological diagnosis if clinically indicated

Place in the celiac disease serological workup

Celiac serology includes several complementary markers whose combination optimizes diagnostic sensitivity and specificity. IgA EMA are distinguished by their very high specificity, at the cost of slightly lower sensitivity than IgA anti-tTG2 in certain subgroups, particularly children under two years of age.

Marker	Sensitivity	Specific	Main use
Anti-TG2 IgA	90 – 98 %	95 – 99 %	First-line test, quantitative, follow-up
Anti-endomysium IgA	85 – 95 %	97 – 99 %	Confirmation, ambiguous cases, high specificity
Anti-DGP IgG	80 – 95 %	90 – 96 %	IgA Deficiency, Children < 2 years
Anti-gliadin native IgA/IgG	Low to moderate	Weak	Discontinued in common practice, not recommended

ℹ️ Celiac serology loses its diagnostic value if the patient is already on a gluten-free diet at the time of the test. A gluten-containing diet must be maintained for at least 6 weeks before testing, ideally 3 months, to ensure the reliability of serological results.

Diagnostic confirmation and duodenal biopsy

A positive result for IgA anti-endomysial antibodies strongly suggests celiac disease, but diagnostic confirmation relies on a biopsy of the duodenal mucosa via upper endoscopy. Histological analysis looks for classical lesions according to the Marsh classification, ranging from an increase in intraepithelial lymphocytes (stage 1) to total villous atrophy (stage 3c).

In children, the new guidelines from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) allow, under certain strict conditions, for diagnosis without biopsy when anti-tissue transglutaminase IgA (anti-TG2 IgA) antibodies are very strongly positive and anti-endomysial IgA (AEM IgA) antibodies are confirmed. This approach remains under the guidance of a paediatric specialist.

Serological monitoring on a gluten-free diet

Once celiac disease is confirmed and a gluten-free diet is established, serology is used as a monitoring tool to assess dietary adherence and mucosal response. Normalization of EMA IgA typically occurs within 12 to 24 months on a strict diet, but may be slower in some patients.

Recommended check-up dosage at 6 and 12 months after starting the gluten-free diet
Persistence of positivity suggests intentional or unintentional food transgression (hidden gluten)
Annual or biennial follow-up recommended long-term for the detection of serological relapses
Additional nutritional assessment: iron, folate, vitamin B12, vitamin D, zinc in case of prior malabsorption
Baseline and follow-up bone densitometry in patients with osteopenia or osteoporosis

Consult at Clinique Omicron

Clinique Omicron offers a comprehensive digestive and immune assessment for patients presenting with symptoms suggestive of celiac disease or whose serological results require clinical interpretation. At its service points in Quebec, physicians and nurse practitioners (NPs) can prescribe celiac serology tailored to the patient's context, including the measurement of EMA IgA, total IgA, and complementary markers based on their profile. The clinic also provides follow-up care for already diagnosed celiac patients, in coordination with gastroenterology and nutrition specialists. To book an appointment at one of the service points on the South Shore or other branches in Quebec, visit cliniqueomicron.ca or contact the clinic directly.

The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.

Omicron Clinic

Need to consult a doctor?

Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.

No appointment necessary Private clinic Family doctor

Insurance receipts. 7j/7. No family doctor required.

At the clinic

At home

On line

Health assessments

Our programs